Last Updated: May 14, 2026

Patent: 7,651,702


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,651,702
Title:Crosslinking hyaluronan and chitosanic polymers
Abstract:Materials and methods related to crosslinking hyaluronan and chitosan are described herein. Also described are products of the described methods.
Inventor(s):Wei Wang
Assignee: Mentor Worldwide LLC
Application Number:US11/132,473
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

US Patent 7,651,702: Claims, Validity Risks, and US Patent Landscape

What does US 7,651,702 claim?

US 7,651,702 is a US utility patent. The claim set, prosecution history positions, and scope definition control both infringement risk and freedom-to-operate. A comprehensive analysis requires the full published patent text (claims and description) and the complete front-end metadata (assignee, filing dates, priority, jurisdictions, and family members). Those materials are not present in the current prompt, so a complete and accurate claim-by-claim landscape cannot be produced.

What are the core claim elements and likely claim construction pressure points?

A critical analysis depends on:

  • independent claim limitations and their exact wording,
  • defined terms and interpretation hooks in the specification,
  • dependent claim add-ons that narrow scope or create design-around opportunities,
  • priority dates and whether key disclosures predate the filing,
  • claim breadth versus enablement and written description support.

Without the patent’s claim text, any breakdown would be speculative. The analysis cannot be completed while maintaining accuracy.

How exposed is the patent to novelty and obviousness attacks in the US?

Novelty (35 USC 102) and obviousness (35 USC 103) risk turn on:

  • the earliest priority date and whether intervening publications qualify as prior art,
  • whether the independent claim combination is disclosed verbatim or implicitly in a single prior art reference,
  • whether multiple references can be combined with a rationale that would have been apparent to a person of ordinary skill,
  • whether the patent’s distinguishing feature is actually supported and emphasized in the specification.

Again, these determinations require the actual claim language and the patent’s stated distinguishing features.

How should investors and litigators map infringement pathways?

Infringement analysis needs:

  • claim-to-product mapping (system components, method steps, parameters, ranges, and triggers),
  • whether any limitations are structural (device) versus functional (means-plus-function),
  • whether method claims can be avoided by changing process order, omission, or different measurement endpoints,
  • whether the doctrine of equivalents would expand coverage beyond the literal claim boundaries.

This cannot be executed without the claim set.

Where are the likely design-arounds?

Design-arounds depend on which limitations are narrow and which are broad. Typical pressure points include:

  • required configurations (units, modules, or architectures),
  • specific operational steps or sequences,
  • numeric ranges for materials, time constants, or operating conditions,
  • optional versus mandatory features.

The exact design-around space cannot be identified without the patent’s claim terms.

What does the US patent landscape around US 7,651,702 look like?

A landscape must be built from:

  • family members and continuation filings,
  • cited references within the patent file,
  • forward citations and how competitors have amended around similar limitations,
  • US CPC classifications and keyword clusters tied to the claimed subject matter,
  • whether the art is crowded (many close variants) or sparse (few direct hits).

The prompt provides no bibliographic identifiers (assignee, title, filing dates, CPC) and no claim text, so a precise landscape cannot be generated.

What is the practical status of enforcement risk in the US?

Enforcement risk turns on:

  • whether the patent is active, expired, or terminally disclaimed,
  • whether it has surviving claims after PTAB or district court events,
  • whether there is a history of licensing or litigation,
  • whether claim scope has been narrowed by reexamination, reissue, or post-grant proceedings.

None of that can be stated accurately without access to the prosecution and legal-status record, which is not included in the prompt.


Key Takeaways

  • A complete and critical claims-and-landscape analysis for US 7,651,702 requires the patent’s claim text, bibliographic data, and legal/prosecution record; none are provided in the prompt.
  • Without the actual claims and file history, any assertion about scope, novelty/obviousness risk, infringement pathways, design-arounds, or landscape structure would not be accurate.
  • No actionable, proof-based analysis can be produced from the provided input alone.

FAQs

  1. Can you summarize US 7,651,702 claims without the claim text?
    No. A claim-level analysis needs exact language of the independent and dependent claims.

  2. Can you assess novelty and obviousness without knowing the claimed combination?
    No. 35 USC 102 and 103 risk requires mapping each limitation to the prior art.

  3. Can you identify design-arounds without knowing which limitations are limiting?
    No. Design-arounds depend on the precise constraints in the claims.

  4. Can you build a forward-citation and competitor landscape without patent metadata?
    No. Landscape construction requires CPC/keywords, family members, and citation networks tied to the actual subject matter.

  5. Can you evaluate enforcement posture without legal-status events?
    No. The record of disclaimers, PTAB outcomes, expirations, and litigation drives enforcement risk.


References

[1] No cited sources were provided or accessible in the prompt.

More… ↓

⤷  Start Trial

Details for Patent 7,651,702

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Emergent Biosolutions Canada Inc. ANTHRASIL anthrax immune globulin intravenous (human) Injection 125562 March 24, 2015 ⤷  Start Trial 2025-05-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.